In the News
Stay up to date with the latest news from Providence Cancer Institute Oregon. Sign up for our monthly research newsletter.
Follow us on social media:
New trials available at Earle A. Chiles Research Institute for patients with human epidermal growth factor receptor 2 positive (HER2+) colorectal cancer and patients with cholangiocarcinoma.
In honor of Social Work Month we recognize the incredible contributions of oncology social workers.
A new trial offered at Providence Cancer Institute is enrolling patients with early-stage HR-positive and HER2-negative breast cancer.
As part of an international data-sharing consortium of leading cancer centers, Providence Cancer Institute and Swedish Cancer Institute work together to provide genomic data to Project GENIE.
Using MRI-guided radiation, Providence radiation oncologists can precisely target tumors for destruction while minimizing damage to surrounding normal tissue.
A new clinical trial offered at Providence Cancer Institute to study the safety and effectiveness of two different treatments for people under age 70 with previously untreated non-GCB DLBCL.
Providence Cancer Institute highlights a year of engaging with and supporting our patients, partner organizations and community.
Providence Cancer Institute is offering a phase III trial for patients with gynecologic cancers and two early phase trials that will study new medications in treating solid tumors.
Providence currently accepting applications for an Immuno-Oncology Research Fellowship being offered through Earle A. Chiles Research Institute.
Bernard A. Fox, Ph.D., leader of the Laboratory of Molecular and Tumor Immunology honored by the Society for Immunotherapy of Cancer for legacy of public service.
Providence Cancer Institute to hold two virtual events on the benefits of integrative medicine for patients.
Providence Cancer Institute one of only a few sites worldwide offering two new clinical trials for solid tumors and lung cancer.
Providence Cancer Institute is currently recruiting participants for three new clinical studies offered for people with HER2-neu negative breast cancer.
Leading lung cancer professionals to gather in November for premier oncology summit.
Providence gynecologic oncologist Christopher Darus, M.D. shares the latest research and promising treatments for gynecologic cancers.
Providence hematology expert offers the most updated information about lymphoma, treatment options and helpful community resources.
New investigator-initiated clinical trial available only at Providence Cancer Institute will evaluate the safety and efficacy of targeted therapy combination for treating thyroid cancer.
Providence Cancer Institute experts share their insights on recent advances in melanoma research and care, and tips on communicating with loved ones in a virtual symposium.
New Providence-sponsored study may provide new insights into the efficacy of shorter duration radiation and chemotherapy treatment before surgery for people with stage II/III rectal cancer
Results of a phase II clinical trial shows that adding an immunotherapy pill to standard pre-surgery treatment of colorectal cancer patients doubled the successful outcomes.